Financial Snapshot

Revenue
$10.12M
TTM
Gross Margin
Net Earnings
-$280.5M
TTM
Current Assets
Q3 2024
Current Liabilities
Q3 2024
Current Ratio
1775.77%
Q3 2024
Total Assets
Q3 2024
Total Liabilities
Q3 2024
Book Value
$1.503B
Q3 2024
Cash
Q3 2024
P/E
-16.13
Nov 29, 2024 EST
Free Cash Flow
-$188.5M
TTM

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2023 2022 2021 2020 2019 2018
Revenue $9.560M $9.224M $9.326M $6.787M $2.319M $379.0K
YoY Change 3.64% -1.09% 37.41% 192.67% 511.87%

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2023 2022 2021 2020 2019 2018
Revenue $9.560M $9.224M $9.326M $6.787M $2.319M $379.0K
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2023 2022 2021 2020 2019 2018
Selling, General & Admin $54.19M $37.73M $26.20M $13.46M $5.110M $2.440M
YoY Change 43.61% 44.05% 94.61% 163.41% 109.43%
% of Gross Profit
Research & Development $191.0M $150.4M $101.2M $37.60M $14.54M $8.436M
YoY Change 26.97% 48.65% 169.09% 158.63% 72.34%
% of Gross Profit
Depreciation & Amortization $2.100M $1.400M $600.0K $400.0K $300.0K $383.0K
YoY Change 50.0% 133.33% 50.0% 33.33% -21.67%
% of Gross Profit
Operating Expenses $245.2M $188.1M $127.4M $51.06M $19.65M $10.88M
YoY Change 30.31% 47.7% 149.45% 159.85% 80.67%
Operating Profit -$235.6M -$178.9M -$118.1M -$44.28M -$17.33M -$10.50M
YoY Change 31.68% 51.56% 166.62% 155.46% 65.1%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2023 2022 2021 2020 2019 2018
Interest Expense $23.97M $0.00 $104.0K $209.0K $7.387M $718.0K
YoY Change -100.0% -50.24% -97.17% 928.83%
% of Operating Profit
Other Income/Expense, Net $23.38M $4.918M -$62.00K -$78.00K -$7.402M -$718.0K
YoY Change 375.36% -8032.26% -20.51% -98.95% 930.92%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2023 2022 2021 2020 2019 2018
Pretax Income -$212.2M -$174.0M -$118.0M -$44.36M -$24.73M -$11.22M
YoY Change 21.97% 47.44% 166.03% 79.38% 120.41%
Income Tax $0.00 $0.00 $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$212.2M -$174.0M -$118.0M -$44.36M -$24.73M -$11.22M
YoY Change 21.97% 47.44% 166.06% 79.33% 120.52%
Net Earnings / Revenue -2219.87% -1886.33% -1265.38% -653.53% -1066.58% -2959.37%
Basic Earnings Per Share -$2.91 -$3.34 -$2.85 -$2.05
Diluted Earnings Per Share -$2.91 -$3.34 -$2.849M -$2.048M -$559.5K -$253.8K

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2023 2022 2021 2020 2019 2018
Cash & Short-Term Investments $595.4M $610.7M $405.5M $328.1M $94.60M $3.100M
YoY Change -2.52% 50.59% 23.6% 246.83% 2951.61%
Cash & Equivalents $185.1M $340.4M $320.4M $321.5M $94.60M $3.100M
Short-Term Investments $410.3M $270.3M $85.10M $6.700M
Other Short-Term Assets $14.85M $12.22M $5.598M $3.500M $1.100M $200.0K
YoY Change 21.58% 118.2% 59.94% 218.18% 450.0%
Inventory
Prepaid Expenses
Receivables $1.105M
Other Receivables $0.00
Total Short-Term Assets $611.3M $622.9M $411.1M $331.7M $95.70M $3.200M
YoY Change -1.87% 51.52% 23.95% 246.6% 2890.63%
Property, Plant & Equipment $16.65M $15.01M $15.59M $1.900M $600.0K $700.0K
YoY Change 10.95% -3.72% 720.47% 216.67% -14.29%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $596.0K $849.0K $850.0K $300.0K $600.0K $0.00
YoY Change -29.8% -0.12% 183.33% -50.0%
Total Long-Term Assets $17.25M $15.86M $16.44M $2.200M $1.200M $800.0K
YoY Change 8.77% -3.53% 647.23% 83.33% 50.0%
Total Assets $628.6M $638.8M $427.6M $333.9M $96.90M $4.000M
YoY Change
Accounts Payable $8.809M $32.57M $14.09M $7.700M $1.900M $1.600M
YoY Change -72.96% 131.25% 82.92% 305.26% 18.75%
Accrued Expenses $43.51M $14.30M $10.71M $3.200M $1.700M $300.0K
YoY Change 204.34% 33.49% 234.66% 88.24% 466.67%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $2.800M $2.700M
YoY Change 3.7%
Total Short-Term Liabilities $80.68M $51.91M $29.66M $14.60M $10.20M $4.600M
YoY Change 55.43% 75.02% 103.14% 43.14% 121.74%
Long-Term Debt $0.00 $0.00 $0.00 $0.00 $1.800M $7.600M
YoY Change -100.0% -76.32%
Other Long-Term Liabilities $47.11M $8.817M $16.49M $13.10M $15.50M $200.0K
YoY Change 434.32% -46.54% 25.89% -15.48% 7650.0%
Total Long-Term Liabilities $47.11M $8.817M $16.49M $13.10M $17.30M $7.800M
YoY Change 434.32% -46.54% 25.89% -24.28% 121.79%
Total Liabilities $127.8M $60.73M $46.15M $27.70M $27.50M $12.40M
YoY Change 110.44% 31.58% 66.61% 0.73% 121.77%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2023 2022 2021 2020 2019 2018
Basic Shares Outstanding 73.01M shares 52.16M shares 41.43M shares 21.66M shares
Diluted Shares Outstanding 73.01M shares 52.16M shares 41.43M shares 21.66M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $4.5254 Billion

About Avidity Biosciences, Inc.

Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). The company is headquartered in San Diego, California and currently employs 253 full-time employees. The company went IPO on 2020-06-12. The firm is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). The AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Its advancing and expanding pipeline has three programs in clinical development. AOC 1001 is designed to treat people with myotonic dystrophy type 1 (DM1) and is in phase I/II development with the ongoing MARINA open label extension study (MARINA-OLE). AOC 1044 is designed for people with Duchenne muscular dystrophy and is in phase I/II development with the EXPLORE44 trial. AOC 1020 is designed to treat people living with facioscapulohumeral muscular dystrophy (FSHD) and is in Phase I/II development with the FORTITUDE trial.

Industry: Pharmaceutical Preparations Peers: Vericel Corp Crinetics Pharmaceuticals, Inc. Emergent BioSolutions Inc. ENANTA PHARMACEUTICALS INC Forma Therapeutics Holdings, Inc. ImmunoGen, Inc. MADRIGAL PHARMACEUTICALS, INC. Morphic Holding, Inc. REGENXBIO Inc.